Benitec Biopharma Inc. (BNTC): who owns it and who trades it
As of Nov 16, 2026, BNTC insiders reported 12 purchases worth $2.4M in the last 12 months. The largest buyer was Aaron Cowen (Director), with $1.9M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Benitec Biopharma
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns BNTC
87 funds and institutions reported BNTC shares worth $465M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Montanova Capital, LLC with 33.6%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Montanova Capital, LLC | 11.55M | 33.62% | $155M | No change |
| Nantahala Capital Management, LLC | 2.98M | 8.66% | $39.8M | +107% |
| Jupiter Topco LLC | 2.48M | 7.21% | $33.1M | New |
| Franklin Resources Inc | 2.41M | 7.02% | $32.3M | +1% |
| Adage Capital Partners Gp, L.l.c. | 2.12M | 6.17% | $28.4M | No change |
| Ra Capital Management, L.P. | 1.85M | 5.39% | $24.8M | No change |
| BlackRock, Inc. | 1.41M | 4.10% | $18.8M | +19% |
| Simplify Asset Management Inc. | 1.01M | 2.93% | $13.5M | +79% |
| Vanguard Capital Management LLC | 954,533 | 2.78% | $12.8M | +2% |
| Infinitum Asset Management, LLC | 923,006 | 2.69% | $12.3M | No change |
| Millennium Management LLC | 921,299 | 2.68% | $12.3M | +41% |
| Alyeska Investment Group, L.P. | 750,000 | 2.18% | $10M | No change |
| Silverarc Capital Management, LLC | 679,826 | 1.98% | $9.1M | -5% |
| Balyasny Asset Management L.P. | 650,503 | 1.89% | $8.7M | -1% |
| Geode Capital Management, LLC | 611,736 | 1.78% | $8.2M | +17% |
| Ameriprise Financial Inc | 401,245 | 1.17% | $5.4M | +26% |
| State Street Corp | 377,973 | 1.10% | $5.1M | +12% |
| MYDA Advisors LLC | 250,000 | 0.73% | $3.3M | +11% |
| Schonfeld Strategic Advisors LLC | 235,357 | 0.69% | $3.1M | +54% |
| AWM Investment Company, Inc. | 187,977 | 0.55% | $2.5M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, BNTC insiders reported $2.4M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 29, 2025 | Aaron Cowen +3 | Director | Purchase | 65,800 | $13.44 | $884K | Form 4 |
| Dec 29, 2025 | Aaron Cowen +3 | Director | Purchase | 11,587 | $13.44 | $156K | Form 4 |
| Dec 26, 2025 | Aaron Cowen +3 | Director | Purchase | 14,320 | $13.10 | $188K | Form 4 |
| Dec 26, 2025 | Aaron Cowen +3 | Director | Purchase | 2,516 | $13.10 | $33K | Form 4 |
| Dec 23, 2025 | Aaron Cowen +3 | Director | Purchase | 7,400 | $12.85 | $95.1K | Form 4 |
| Dec 23, 2025 | Aaron Cowen +3 | Director | Purchase | 42,600 | $12.85 | $547K | Form 4 |
| Dec 22, 2025 | Averill Madison Master Fund, Ltd. +3 | 10% owner | Purchase | 16,650 | $12.08 | $201K | Form 4 |
| Dec 22, 2025 | Averill Madison Master Fund, Ltd. +3 | 10% owner | Purchase | 2,892 | $12.08 | $34.9K | Form 4 |
| Dec 19, 2025 | Averill Madison Master Fund, Ltd. +3 | 10% owner | Purchase | 2,434 | $11.48 | $27.9K | Form 4 |
| Dec 19, 2025 | Averill Madison Master Fund, Ltd. +3 | 10% owner | Purchase | 13,950 | $11.48 | $160K | Form 4 |
| Dec 18, 2025 | Averill Madison Master Fund, Ltd. +3 | 10% owner | Purchase | 8,700 | $11.24 | $97.8K | Form 4 |
| Dec 18, 2025 | Averill Madison Master Fund, Ltd. +3 | 10% owner | Purchase | 1,515 | $11.24 | $17K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Aaron Cowen | Director, 10% owner | $1.9M | – | Dec 29, 2025 |
| Averill Madison Master Fund, Ltd. | 10% owner | $539K | – | Dec 22, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BNTC short interest
Moderate short interest. 5.7% of BNTC shares are sold short: about 1 share in 17. Over the last 12 reports the number of shares short went down 11%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.99M BNTC shares were sold short, 5.7% of the shares outstanding, up 0.1% from the report before. At the average daily volume of 176,530 shares, buying them all back would take about 11.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.99M | 5.72% | +0% | 176,530 | 11.3 |
| Oct 15, 2026 | 1.99M | 5.71% | -2% | 197,761 | 10.1 |
| Sep 30, 2026 | 2.04M | 5.85% | -7% | 200,147 | 10.2 |
| Sep 15, 2026 | 2.19M | 6.27% | -1% | 109,463 | 20.0 |
| Aug 31, 2026 | 2.21M | 6.45% | +5% | 154,962 | 14.3 |
| Aug 14, 2026 | 2.11M | 6.13% | -2% | 211,986 | 9.9 |
| Jul 31, 2026 | 2.15M | 6.25% | -5% | 80,283 | 26.7 |
| Jul 15, 2026 | 2.27M | 6.61% | +2% | 96,657 | 23.5 |
| Jun 30, 2026 | 2.23M | 6.49% | -7% | 214,322 | 10.4 |
| Jun 15, 2026 | 2.41M | 7.00% | +3% | 83,370 | 28.9 |
| May 29, 2026 | 2.33M | 6.79% | +4% | 75,779 | 30.8 |
| May 15, 2026 | 2.25M | 6.55% | -3% | 97,935 | 23.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Benitec Biopharma company events
Benitec Biopharma filed 9 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, auditor). The latest was on Oct 28, 2026.
- Oct 28, 2026AnnouncementShared information with investors. Filing
- Oct 5, 2026AnnouncementShared information with investors. Filing
- Sep 30, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
- Sep 24, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
- Sep 14, 2026ResultsReleased financial results. Filing
- May 29, 2026LeadershipThe Board of Directors of Benitec Biopharma Inc. appointed David Friedman to serve as a director of the Board, effective as of such date. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Feb 12, 2026ResultsReleased financial results. Filing
- Dec 2, 2025VoteReported shareholder vote results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Benitec Biopharma financials
Famous investors that hold BNTC
3 of the 50 well-known investors we track reported holding BNTC in their latest 13F filing. The largest position is Israel Englander's, worth $7.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 760,251 | $7.6M | 0.0% | -17% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 271,278 | $2.7M | 0.0% | +233% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 22,211 | $222K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Benitec Biopharma Inc. (BNTC) stock
Who owns the most BNTC stock?
The largest reported owner of Benitec Biopharma Inc. (BNTC) is Montanova Capital, LLC, with 33.6% of the company. In total, 87 funds and institutions reported holding BNTC at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are BNTC insiders buying or selling?
In the last 12 months, BNTC insiders reported 12 open-market purchases worth $2.4M and no sales. The latest trade was on Dec 29, 2025. See every trade.
What is the short interest in BNTC?
As of Oct 30, 2026, 1.99M BNTC shares were sold short, 5.7% of the shares outstanding, up 0.1% from the report before. At the average daily volume of 176,530 shares, buying them all back would take about 11.3 trading days (days to cover). See the history.
Which famous investors hold BNTC?
3 of the 50 well-known investors we track reported BNTC in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $7.6M. See all holders.
Executive pay
Benitec Biopharma's chief executive was paid a total of $6.5M for the year ended Jun 30, 2026, down 75% from $25.9M the year before. In the last 12 months, Benitec Biopharma's executives and directors bought $1.9M of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.